Cassava Sciences

#9238

Rank

$103.86M

Marketcap

United States

Country

Leadership team

Mr. Eric J. Schoen (Chief Financial Officer)

Dr. Nadav Friedmann M.D., Ph.D. (Chief Medical Officer & Director)

Mr. Remi Barbier (Founder, Chairman, Pres & CEO)

Products/ Services

Biopharma, Biotechnology, Life Science, Medical, Neuroscience, Pharmaceutical

Headquarters

Austin, Texas, United States

Established

1998

Company Registration

SEC CIK number: 0001069530

Traded as

SAVA

Social Media

URL

https://www.cassavasciences.com

Overview

Location

Recognition and Award

References

Summary

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

History

Founding

Cassava Sciences was founded by Remi Barbier in May 1998 as Pain Therapeutics, focusing on opioids and chronic pain. Barbier first heard of the research led by Stanley M. Crain at the Albert Einstein College of Medicine in New York City around 1993. Crain invited Barbier to his lab and explained the potential pharmaceutical and financial benefits. In 1998, Barbier started Pain Therapeutics, Inc. in South San Francisco, California, with an initial investment of $1 million.

Name change

Following the fourth FDA rejection of one of its experimental pain drugs, Remoxy, Cassava announced in August 2018 it would reorganize the company to focus on products for treating and diagnosing Alzheimer's. In 2019, the company changed its name to Cassava Sciences.

Mission

Cassava Sciences is dedicated to advancing science in order to discover treatments for neurological diseases such as Alzheimer’s, Huntington’s, and Parkinson’s Disease.

Vision

To leverage Simalevo technology to discover and develop novel therapies for neurological diseases and become a leader in the field.

Key Team

Dr. James W. Kupiec M.D. (Chief Clinical Devel. Officer)

Dr. George Thornton (Sr. VP of Technology)

Mr. R. Christopher Cook (Sr. VP & Gen. Counsel)

Mr. Michael Zamloot (Sr. VP of Technical Operations)

Dr. Michael Marsman Pharm.D. (Sr. VP of Regulatory Affairs)

Dr. Lindsay H. Burns Ph.D. (Sr. VP of Neuroscience)

Recognition and Awards

Cassava Sciences has been recognized for its innovative technology and research. The company has won numerous awards, including the 2016 Golden Pointer Award for 'Best Idea for a Startup', the 2020 International Venture Award, and the 2020 BioPharma Award for 'Best in Biotech Therapy'.